NEAL KLEIMAN to Risk
This is a "connection" page, showing publications NEAL KLEIMAN has written about Risk.
Connection Strength
0.181
-
Propensity-Matched 1-Year Outcomes Following Transcatheter Aortic Valve Replacement in Low-Risk Bicuspid and Tricuspid Patients. JACC Cardiovasc Interv. 2022 03 14; 15(5):511-522.
Score: 0.038
-
Outcomes in the Randomized CoreValve US Pivotal High Risk Trial in Patients With a Society of Thoracic Surgeons Risk Score of 7% or Less. JAMA Cardiol. 2016 11 01; 1(8):945-949.
Score: 0.026
-
Transcatheter Aortic Valve Replacement Versus Surgery in Women at High Risk for Surgical Aortic Valve Replacement (from the CoreValve US High Risk Pivotal Trial). Am J Cardiol. 2016 Aug 15; 118(4):560-6.
Score: 0.025
-
Bioprosthetic Mitral Transcatheter Transapical Valve-in-Valve Implantation for Mitral Stenosis in an End-Stage Renal Disease Patient. J Card Surg. 2015 Sep; 30(9):697-700.
Score: 0.024
-
Health status after transcatheter aortic valve replacement in patients at extreme surgical risk: results from the CoreValve U.S. trial. JACC Cardiovasc Interv. 2015 Feb; 8(2):315-323.
Score: 0.023
-
Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry. Circ Cardiovasc Interv. 2011 Oct 01; 4(5):463-73.
Score: 0.018
-
Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA. 2007 May 09; 297(18):2001-9.
Score: 0.014
-
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. JAMA. 2005 Nov 23; 294(20):2594-600.
Score: 0.012